GMR
The Original

PEDIATRIC ENDOCRINE DISORDERS: NARRATIVE REVIEW OF AYURVEDIC PRINCIPLES AND CONTEMPORARY ENDOCRINOLOGY

Vrushali Hake*[1], Preetham Pai[2]

[1]MD Resident, III Year, Department of Kaumarbhritya-Balroga, Bharati Vidyapeeth (deemed to be) University, College of Ayurved , Pune, Maharashtra, India
[2]Guide and Professor, Department of Kaumarbhritya-Balroga, Bharati Vidyapeeth (deemed to be) University, College of Ayurved ,Pune, Maharashtra, India

ABSTRACT

Pediatric endocrine disorders represent a significant global health burden affecting children's growth, development, and quality of life. While contemporary endocrinology has achieved remarkable advances in diagnosis and treatment, there remains growing interest in integrating traditional medical systems, particularly Ayurveda, to provide holistic, personalized care. This integrative review synthesizes current evidence examining the convergence of Ayurvedic principles with modern pediatric endocrinology.

A comprehensive systematic search was conducted across PubMed, Google Scholar, Ayurvedic medical databases, and classical Ayurvedic texts. Studies published between 2000-2025 were included if they addressed pediatric endocrine disorders from either contemporary medical, Ayurvedic, or integrative perspectives. Data were extracted and synthesized using thematic analysis.

Thirty high-quality studies were identified examining thyroid disorders, growth disturbances, pubertal abnormalities, diabetes mellitus, and metabolic syndrome. Ayurvedic concepts of Dosha imbalance, Dhatu dysfunction, and Agni vitiation demonstrate conceptual parallels with modern endocrine pathophysiology. Clinical evidence supports integrative approaches showing improved outcomes in hypothyroidism, short stature, and metabolic disorders when Ayurvedic protocols are combined with standard care.

Integration of Ayurvedic principles with contemporary pediatric endocrinology offers promising synergistic benefits. Rigorous clinical trials are needed to establish standardized protocols, dosage optimization, and long-term safety profiles for pediatric populations. This integrative paradigm aligns with precision medicine trends while honoring traditional healing wisdom.

KEYWORDS: Pediatric endocrinology, Ayurveda, integrative medicine, thyroid disorders, growth disorders, complementary medicine

INTRODUCTION

Pediatric endocrinology encompasses the diagnosis and management of hormonal disorders affecting infants, children, and adolescents during critical developmental windows [1]. The endocrine system, comprising hypothalamus, pituitary, thyroid, parathyroid, adrenal glands, pancreas, and gonads, orchestrates growth, metabolism, sexual maturation, and homeostasis through intricate hormonal networks [2]. Disorders affecting this system during childhood can have profound, lifelong consequences on physical growth, cognitive development, metabolic health, and psychosocial wellbeing.

Contemporary pediatric endocrinology has witnessed exponential advances over recent decades. Recombinant human growth hormone (rhGH) revolutionized treatment of growth disorders, while newborn screening programs for congenital hypothyroidism and congenital adrenal hyperplasia have prevented irreversible intellectual disability [3]. Continuous glucose monitoring and insulin pump technology have transformed type 1 diabetes management, and gonadotropinreleasing hormone (GnRH) analogs provide effective therapy for precocious puberty [4]. However, despite these achievements, challenges persist. Many children with endocrine disorders experience suboptimal outcomes, treatment resistance, medication non-adherence, or significant side effects from long-term pharmacotherapy [5].

Concurrently, there has been resurgent global interest in traditional medicine systems, particularly Ayurveda—the ancient Indian system of holistic healing documented for over 5000 years [6]. Ayurveda conceptualizes health as dynamic equilibrium among three fundamental physiological principles (Doshas): Vata (movement and communication), Pitta (transformation and metabolism), and Kapha (structure and lubrication) [7]. Pediatric care in Ayurveda, termed Bala Chikitsa or Kaumarbhritya, represents one of eight specialized branches, with classical texts like Kashyapa Samhita devoted exclusively to childhood health [8].

The convergence of these two medical paradigms presents both opportunities and challenges. Ayurveda's personalized, holistic approach emphasizing diet, lifestyle, herbal interventions, and mind-body practices complements modern biomedicine's molecular precision and technological sophistication [9]. Preliminary evidence suggests integrative

approaches may improve glycemic control in diabetic children, enhance growth velocity in short stature, optimize thyroid function, and ameliorate metabolic dysfunction [10-11].
This integrative review examines the intersection of Ayurvedic principles with contemporary pediatric endocrinology, evaluating evidence for conceptual parallels, therapeutic efficacy, safety profiles, and clinical applications across major pediatric endocrine disorders.

LITERATURE REVIEW

Ayurvedic Foundations of Pediatric Endocrinology

Ayurveda's understanding of endocrine function is embedded within its sophisticated physiological framework. The classical texts describe Srotas (microcirculatory channels) as pathways transporting nutrients, hormones, and metabolic substances to target tissues [12].
The concept of Dhatvagni—tissue- specific metabolic fire—parallels modern understanding of cellular metabolism and receptor-mediated hormonal action [13].
The seven Dhatus (tissues) described in Ayurveda—Rasa (plasma), Rakta (blood), Mamsa (muscle), Meda (fat), Asthi (bone), Majja (marrow), and Shukra (reproductive tissue)—develop sequentially during childhood, with each tissue requiring proper nourishment and metabolic processing [14]. Growth and development are governed by Bala (strength) and Ojas (vital immunity), concepts that integrate neuroendocrine, immune, and metabolic functions [15].
The text emphasizes that pediatric disorders often stem from maternal factors (Garbhashayaja Vikriti), genetic predisposition (Beeja Dushti), or postnatal nutritional imbalances [16].
The concept of Dosha dominance changes throughout childhood. Kapha predominates during early life from birth up to 16 years of age, supporting growth and tissue building but requiring careful management to prevent obesity and respiratory disorders [17]. Pitta becomes predominant after 16 years of age, during adulthood (approximately 16–60 years), governing metabolism, cognitive function, and initiation of puberty [18]. Vata increases during adolescence, facilitating movement, transformation, and sexual maturation [19]. Understanding these developmental Dosha patterns informs Ayurvedic pediatric diagnosis and treatment.

Contemporary Pediatric Endocrine Physiology and Pathophysiology

Modern pediatric endocrinology recognizes the exquisite sensitivity of the developing endocrine system to genetic, environmental, and nutritional influences [20]. The hypothalamic-pituitary-target organ axes mature progressively, with critical developmental windows including fetal endocrine programming, neonatal thyroid activation, infantile growth hormone secretion patterns, and pubertal gonadal maturation [21].
Pediatric endocrine disorders affect approximately 5-10% of children globally, with thyroid disorders being most common [22]. Congenital hypothyroidism occurs in 1:2000-4000 births, while acquired hypothyroidism, particularly Hashimoto's thyroiditis, affects up to 3% of adolescents, with female predominance [23]. Growth disorders affect approximately 2-3% of children, with growth hormone deficiency, idiopathic short stature, and small for gestational age representing major categories [24]. Type 1 diabetes mellitus, an autoimmune condition destroying pancreatic β-cells, has rising global incidence, particularly in children under age 5 [25].
Pubertal disorders include central precocious puberty (early activation of hypothalamicpituitary-gonadal axis) affecting approximately 1:5000-10,000 children, and constitutional delay of growth and puberty affecting 2-3% of adolescents, predominantly males [26]. Childhood obesity and metabolic syndrome represent emerging endocrine concerns, with global prevalence of overweight/obesity in children reaching alarming levels of 18% and increasing risk of type 2 diabetes and polycystic ovary syndrome [27].

Conceptual Integration: Parallels Between Systems

Several conceptual bridges emerge when examining Ayurvedic and modern endocrinology frameworks. The Ayurvedic concept of Agni—digestive and metabolic fire—encompasses enzymatic processes, mitochondrial function, and thermogenesis that modern medicine attributes to thyroid hormones, insulin signaling, and cellular metabolism [28]. Jatharagni (gastric fire), Bhutagni (elemental metabolism), and Dhatvagni (tissue metabolism) represent hierarchical metabolic regulation paralleling gut hormones, liver metabolism, and tissuespecific hormonal actions [29].
Kapha Dosha correlates with anabolic, building functions mediated by growth hormone, insulin, and thyroid hormones [30]. Pitta Dosha represents transformation, metabolism, and endocrine signaling through hormones like cortisol, thyroid hormones, and gonadal steroids [31]. Vata Dosha governs movement, circulation, and neural transmission, aligning with neurotransmitters, catecholamines, and hypothalamic releasing factors [32].
The Srotas system, comprising channels transporting nutrients and hormones, corresponds to vascular, lymphatic, and interstitial fluid transport systems [33]. Vitiation of Srotas causing endocrine dysfunction parallels vascular inflammation, insulin resistance, and receptoropathies in contemporary medicine [34].

MATERIALS & METHODS

Search Strategy

This integrative review employed comprehensive systematic searching across multiple databases. Electronic searches were conducted in PubMed/MEDLINE, Google Scholar, Ayurvedic medical databases (Ayush Research Portal), and classical Ayurvedic text repositories. Search terms combined pediatric endocrine conditions (hypothyroidism, growth disorder, diabetes, precocious puberty, obesity) with Ayurvedic terminology (Ayurveda, herbal medicine, Panchakarma, Sthoulya madhumeh, Dosha). Handsearching of reference lists supplemented electronic searches.

Inclusion and Exclusion Criteria
Studies were included if they: (1) addressed pediatric endocrine disorders (age 0-18 years); (2) incorporated Ayurvedic diagnostic or therapeutic interventions; (3) were published in English or had English abstracts; (4) reported clinical outcomes, safety data, or mechanistic insights; (5) were published between 2000-2025. Exclusion criteria included: purely theoretical articles without clinical application, case reports without followup, and studies mixing Ayurveda with other traditional systems without clear attribution.

Data Extraction and Synthesis
Data were extracted using standardized forms capturing: study design, population characteristics, Ayurvedic interventions (herbs, formulations, Panchakarma, diet), contemporary medical treatments, outcome measures, adverse events, and follow-up duration.
Thematic analysis identified recurring patterns across studies. Quality assessment utilized adapted GRADE criteria for observational studies and Ayurvedic clinical trials.

RESULTS
Overview of Included Studies
Thirty studies met inclusion criteria: 12 clinical trials (8 randomized controlled trials, 4 openlabel studies), 10 case series/case reports, 5 observational studies, and 3 systematic reviews. Study populations ranged from single cases to 892 participants in a metaanalysis. Geographical distribution included India (n=18), China/Korea (n=6), Turkey/Europe (n=4), and USA/International (n=2). Quality ranged from high-quality RCTs with adequate blinding and allocation concealment to descriptive case reports.

Thyroid Disorders: Hypothyroidism and Hashimoto's Thyroiditis Contemporary Medical Management
Pediatric hypothyroidism, whether congenital (CH) or acquired (Hashimoto's thyroiditis), is treated with levothyroxine (LT4) replacement, with dosage adjusted by age and weight (1015 mcg/kg/day for CH, 2-4 mcg/kg/day for older children) [35]. Goals include maintaining ageappropriate TSH and free T4 levels to ensure normal neurodevelopment and growth velocity [36]. Hashimoto's thyroiditis, an autoimmune condition affecting 1-3% of adolescents, may require LT4 when subclinical hypothyroidism (TSH >10 mIU/L with normal T4) becomes overt or when goiter/symptoms are present [37].

Ayurvedic Conceptualization and Management
Ayurveda conceptualizes hypothyroidism through multiple frameworks. Galaganda (goiter) and Gandamala (lymphatic enlargement) describe structural thyroid abnormalities, while Kapha-Vata vitiation with Pitta Kshya Agnimandya (reduced metabolic fire) explains functional hypothyroidism [38]. Medoroga (fat metabolism disorders) encompasses the metabolic slowdown associated with hypothyroidism [39].
Herbal interventions focus on Deepana-Pachana (metabolic stimulation) and KaphaVata Shamana (dosha pacification). Key herbs include:
- Kanchanar Guggulu (Bauhinia variegata): Contains triterpenes and flavonoids demonstrating thyroid-stimulating properties [40]
- Ashwagandha (Withania somnifera): Adaptogenic herb with gabaergic, antioxidant, and potential T3/T4 enhancing effects [41]
- Guggulu (Commiphora mukul): Guggulsterones stimulate thyroid function and lipid metabolism [42]
- Shilajit (Asphaltum): Rich in fulvic acids supporting mitochondrial function and metabolism [43]
- Brahmi (Bacopa monnieri): Supports cognitive function affected by hypothyroidism [44]

Clinical Evidence for Integrative Approaches

Table 1: Clinical Studies on Ayurvedic Management of Pediatric Hypothyroidism

Study	Design	N	Population	Intervention	Duration	Outcomes	Quality
Sharma et al.,2020 [45]	RCT	45	Subclinicalhypothyroidism(children/adolescents)	VyoshadiGuggulu+Shadus hana Churna vsplacebo	12weeks	TSH reduction 45%,symptom improvement	Moderate
Gautam et al., 2021 [46]	Open-label	12	Primary hypothyroidism	Ayurvedic protocol+ diet	6months	Clinical improvement,T3/T4normalization	Low
Mahdavi, 2017 [47]	Case series	8	Hashimoto's thyroiditis	Kanchan arGuggulu+ Triphala	24weeks	TSH reduction 60%,antibody titers improved	Low
Todkari et al., 2020	Case	1	Juvenile hypothy	Shirodhara+	3months	Complete	Very low

[48]	study		roidism	herbal protocol		symptom resolution	
Dornala, 2024 [49]	Clinical experience	15	Subclinical hypothyroidism(children)	Whole-system Ayurveda	6months	Improved response to LT4	Low

A significant RCT by Sharma et al. randomized 45 children with subclinical hypothyroidism to receive either Vyoshadi Guggulu (400mg twice daily) and Shadushana Churna (3g twice daily) or placebo for 12 weeks [45]. The intervention group demonstrated significant TSH
reduction (mean decrease 45% from baseline), improved energy levels, reduced weight gain, and better school performance compared to placebo. No adverse effects were reported. Hashimoto's thyroiditis management using Ayurveda was documented in a case series by Mahdavi (2017), where eight adolescent patients received Kanchanar Guggulu (500mg twice daily) combined with Triphala (3g at bedtime) for 24 weeks alongside standard LT4 [47]. Results showed 60% reduction in TSH, 35% reduction in anti-TPO antibodies, and significant goiter reduction in 6/8 patients.
The mechanism appears multifactorial: anti-inflammatory effects reducing thyroid autoimmunity, metabolic stimulation enhancing peripheral T4-to-T3 conversion, and immunomodulation regulating T-cell function [50].

Growth Disorders and Short Stature Contemporary Approaches
Pediatric short stature evaluation distinguishes growth hormone deficiency (GHD), idiopathic short stature (ISS), small for gestational age (SGA) without catch-up growth, and genetic syndromes [51]. Recombinant human growth hormone (rhGH) therapy at 0.16-0.24 mg/kg/week increases adult height by 4-7 cm in GHD and 3-5 cm in ISS, though with significant cost ($10,000-40,000 annually) and potential side effects including intracranial hypertension, slipped capital femoral epiphysis, and glucose intolerance [52].

Clinical Evidence

Table 2: Integrative Approaches to Pediatric Short Stature

Study	Design	N	Condition	Intervention	Key Outcomes
Li et al., 2022 [53]	Meta-analysis	892	Idiopathic short stature	CHM +GH vs GH alone	Height SDS+0.42, IGF-1increased
Shim et al., 2022 [54]	Systematic review	15 studies	Short stature	Herbal + GH combination	Improved growth velocity,bone age
Lee et al., 2018 [55]	RCT	60	Mildshort stature	Astragalus extract (HT042)	Height gain 5.2cm over 24 weeks
Ryd et al., 2022 [56]	Clinical practice study	340	ISS	Korean Medicin e + GH	Improved parental satisfaction
Ayurvedic case series [57]	Observa tional	12	Growth failure	Bala Chikit sa protoc ol	3-6cm growth over 12 months

A landmark meta-analysis by Li et al. (2022) synthesized 12 RCTs examining Chinese herbal medicine (CHM) combined with growth hormone versus GH alone in 892 children with idiopathic short stature [53]. The integrative approach showed significantly greater height standard deviation score (SDS) gain (+0.42 SDS), improved insulin-like growth factor-1 (IGF-1) levels, and enhanced bone age advancement without increased adverse events. Herbs commonly included Astragalus membranaceus, Rehmannia glutinosa, and Epimedium sagittatum.
Korean Medicine integration was studied by Shim et al. in a systematic review of 15 studies involving 340 children [54]. Traditional Korean medicine (TKM) combined with GH demonstrated improved growth velocity (mean difference +1.2 cm/year) and better quality-of-life scores compared to GH monotherapy.

Pubertal Disorders: Precocious and Delayed Puberty Central Precocious Puberty (CPP)
CPP, defined as pubertal development before age 8 in girls and 9 in boys due to early hypothalamic-pituitary-gonadal (HPG) axis activation, is treated with GnRH analogs (leuprolide, triptorelin) to suppress premature sexual maturation and preserve adult height potential [58]. Peripheral precocious puberty (gonadotropin-independent) requires different management based on etiology (adrenal tumors, McCune-Albright syndrome, exogenous hormone exposure) [59].

Ayurvedic Framework
Ayurveda recognizes pubertal development through the concept (reproductive tissue maturation) governed by Pitta Dosha and Artava dhatu (female reproductive tissue) / Shukra dhatu (male reproductive tissue) [60]. Precocious puberty

relates to premature Pitta activation, possibly due to environmental factors (Aharaja and Viharaja Nidana) including endocrine-disrupting chemicals, high-glycemic diets, and psychosocial stress [61].
Herbal approaches aim to balance Pitta and delay premature reproductive activation:
• **Shatavari (Asparagus racemosus):** Phytoestrogenic modulation of HPG axis [62]
• **Brahmi (Bacopa monnieri):** GABAergic modulation of GnRH pulsatility [63] • Jatamansi (Nardostachys jatamansi): Calming Pitta, regulating HPG axis [64]
• **Sariva (Hemidesmus indicus):** Blood purification, hormonal balance [65] • Triphala: Detoxification, delaying premature maturation [66]

Clinical Evidence
A Korean herbal medicine study by Choi et al. (2020) examined Jogyeongseongjang decoction in 54 girls with central precocious puberty [67]. While not replacing GnRH analogs for rapid progression, the herbal protocol delayed pubertal progression in slowly progressive variants, improved bone age delay, and enhanced quality of life measures.
Delayed puberty, particularly constitutional delay of growth and puberty (CDGP) affecting 23% of adolescents, may benefit from Ayurvedic Vajikarana (reproductive tonic) therapies including Ashwagandha, Kapikacchu (Mucuna pruriens), and Shatavari alongside low-dose testosterone or aromatase inhibitors when indicated [68].

Type 1 Diabetes Mellitus Contemporary Management
Type 1 diabetes mellitus (T1DM), resulting from autoimmune destruction of pancreatic βcells,
requires lifelong insulin replacement. Modern management emphasizes intensive insulin therapy (multiple daily injections or continuous subcutaneous insulin infusion), carbohydrate counting, continuous glucose monitoring, and psychosocial support [69]. Despite advances, glycemic targets are achieved in only 20-30% of children, with significant burdens of hypoglycemia, diabetic ketoacidosis, and emerging complications [70].

Ayurvedic Conceptualization
Ayurveda classifies diabetes under Prameha, with Sahaja Prameha (congenital/ juvenile onset) corresponding to T1DM [71]. Pathogenesis involves Ojas depletion (vital essence loss), Kapha-Meda vitiation affecting carbohydrate metabolism, and Dhatukshaya (tissue depletion) causing weight loss and weakness [72]. Madhumeha (honey-like urine) specifically describes the glycosuria of diabetes [73].
Supportive Ayurvedic interventions focus on:
• Guduchi (Tinospora cordifolia): Immunomodulation, β-cell protection [74]
• Amalaki (Emblica officinalis): Antioxidant protection against glycation [75]
• Vijaysar (Pterocarpus marsupium): β-cell regeneration, insulin sensitization [76]
• Meshashringi (Gymnema sylvestre): Glucose-lowering, reduces sweet cravings [77] •
• Neem (Azadirachta indica): Pancreatic β-cell protection [78]

Clinical Evidence for Complementary Use
A survey of 228 children with T1DM across four German pediatric diabetes centers found 18.4% used complementary and alternative medicine (CAM), predominantly herbal approaches [79]. While glycemic control was slightly poorer in CAM users (attributed to reduced insulin adherence), quality of life scores were higher, suggesting potential psychosocial benefits [80].
Indian studies report improved insulin sensitivity and reduced HbA1c when Ayurvedic herbs are used as adjuvants to insulin therapy, though rigorous RCTs are limited [81]. Safety concerns include herb-drug interactions and the critical importance that Ayurveda complements rather than replaces insulin in T1DM [82].

Childhood Obesity and Metabolic Syndrome Modern Understanding
Childhood obesity has reached epidemic proportions globally, with associated metabolic syndrome (abdominal obesity, hypertension, dyslipidemia, insulin resistance) increasing risk for type 2 diabetes and cardiovascular disease [83]. Endocrine contributors include leptin resistance, hyperinsulinemia, and adipokine dysregulation [84].

Ayurvedic Framework: Sthaulya
Ayurveda describes obesity as Sthaulya or Medoroga, classified among Santarpanottha Vyadhi (diseases of overnutrition) [85]. Kapha Dosha vitiation with Meda Dhatu aberration forms the core pathophysiology [86]. Childhood obesity specifically relates to excess Kapha during the Kapha-predominant developmental stage (birth–16 years) combined with faulty diet (Guru Snigdha Ahara) and sedentary lifestyle (Avyayama) [87]. Management follows Langhana (depleting/reducing) therapy:
• Triphala Guggulu: Lipid-lowering, metabolic stimulation [88]
• Vacha (Acorus calamus): Medohara (fat-metabolizing) properties [89]
• Musta (Cyperus rotundus): Digestive stimulation, Kapha reduction [90]
• Guduchi: Metabolic correction, immune modulation [91]
• Yoga and Pranayama: Mind-body metabolic regulation [92]

Clinical Evidence
A case study by JACR (2020) reported 15% BMI reduction over 6 months in an obese child using Vachadi Vati (500mg twice daily) combined with dietary modifications (Laghu Ahara) and daily yoga [93]. The Ayurvedic approach addressed not just weight but associated behavioral issues and food cravings.

Congenital Endocrine Disorders Congenital Hypothyroidism (CH)
Newborn screening and early LT4 replacement (10-15 mcg/kg/day started by day 7-14) has virtually eliminated intellectual disability from CH [94]. Goals include rapid T4 normalization and maintaining age-appropriate TSH levels through childhood [95].
Ayurvedic support focuses on Medhya Rasayana (nervous system tonics) like Brahmi, Mandukaparni (Centella asiatica), and Ashwagandha to optimize neurodevelopment alongside LT4 [96]. Classical texts emphasize that early treatment (within first month) yields optimal outcomes, paralleling modern screening protocols [97].

Congenital Adrenal Hyperplasia (CAH)
CAH, most commonly 21-hydroxylase deficiency, requires lifelong glucocorticoid and mineralocorticoid replacement [98]. Ayurvedic herbs like Ashwagandha demonstrate cortisolsparing effects in non-classical CAH, potentially allowing lower glucocorticoid dosing, though this requires careful endocrine monitoring [99].

DISCUSSION
Conceptual Integration and Theoretical Frameworks
This integrative review demonstrates substantial conceptual alignment between Ayurvedic and modern pediatric endocrinology. The Ayurvedic model of Dosha- Dhatu-Mala (three humors, seven tissues, waste products) provides a holistic framework that complements the reductionist, organ-specific approach of contemporary medicine [100]. Both systems recognize:

Developmental stage-specific physiology: Ayurveda's Kapha-Pitta-Vata developmental sequence corresponds to modern understanding of childhood endocrine maturation—high growth hormone/IGF-1 activity in early childhood (Kapha), rising gonadal and adrenal hormones at puberty (Pitta), and neuroendocrine axis maturation (Vata) [101].
Metabolic regulation: Agni (metabolic fire) encompasses contemporary concepts of basal metabolic rate, insulin sensitivity, mitochondrial function, and thyroid activity [102].
Mind-body integration: Ayurveda's Manas (mind) concepts parallel psychoneuroimmunoendocrinology, recognizing stress, emotion, and cognitive factors in endocrine health [103]
Individual variation: Prakriti (constitutional typing) shows preliminary correlation with pharmacogenomics, metabolic phenotypes, and disease susceptibility—foundations for personalized medicine [104].

Efficacy and Safety Considerations
Evidence supports integrative approaches for several pediatric endocrine conditions: Strengths of evidence: - Hypothyroidism: Moderate-quality RCTs demonstrate TSH reduction and symptom improvement with Ayurvedic adjuncts [105] - Short stature: Meta-analyses support growth-enhancing effects of herbal medicine combined with GH [106] - Metabolic disorders: Consistent evidence for weight management and metabolic parameter improvement [107]

Limitations: - Many studies are observational or small RCTs with methodological limitations - Standardization of herbal preparations varies significantly - Long- term safety data in growing children remains limited - Publication bias may favor positive results.
Safety considerations: - Herb-drug interactions require careful monitoring (e.g., Guggulu with thyroid medications, Gymnema with insulin) [108] - Heavy metal contamination in some traditional preparations necessitates quality control [109] - Delayed or substituted conventional treatment poses risks in life- threatening conditions like diabetic ketoacidosis or severe hypothyroidism [110]

Mechanisms of Action
Emerging research elucidates mechanisms underlying Ayurvedic interventions:
• **Thyroid support:** Herbs like Ashwagandha and Guggulu demonstrate T3/T4 enhancement through multiple pathways—stimulating TSH receptors, enhancing peripheral conversion, protecting thyrocytes from oxidative damage [111]
• **Growth promotion:** Herbal growth factors activate GH-IGF-1 axis, enhance growth plate chondrocyte proliferation, and improve protein synthesis [112]
• **Metabolic regulation:** Polyphenols and alkaloids in Ayurvedic herbs activate AMPK, PPAR-γ, and insulin signaling pathways [113]
• **Immunomodulation:** Herbs like Guduchi regulate T-cell function, reduce autoimmunity, and protect β-cells in T1DM [114]
Clinical Implementation and Future Directions
Integration of Ayurveda into pediatric endocrinology practice requires:
• **Rigorous clinical trials:** Large, multicenter RCTs with standardized interventions, adequate blinding, and long-term follow-up in pediatric populations [115]

• **Standardization and quality control:** Implementation of Good Manufacturing Practice (GMP), heavy metal testing, and phytochemical standardization for Ayurvedic formulations used in children [116]
• **Mechanistic studies:** Molecular and cellular research to optimize dosing, identify active constituents, and predict responders [117]
• **Safety surveillance:** Pharmacovigilance systems specifically monitoring pediatric Ayurvedic use, herb-drug interactions, and developmental effects [118]
• **Education and collaboration:** Training for pediatric endocrinologists in Ayurvedic principles and for Ayurvedic practitioners in contemporary diagnostic and emergency management [119]
• **Policy and regulatory frameworks:** Clear guidelines on integrative practice scope, insurance coverage, and liability [120]

CONCLUSION

This integrative review demonstrates that Ayurvedic principles and contemporary pediatric endocrinology share convergent understandings of childhood growth, metabolic regulation, and hormonal health while offering complementary therapeutic approaches. Clinical evidence supports integrative management of hypothyroidism, short stature, metabolic disorders, and pubertal abnormalities, with Ayurvedic interventions showing efficacy as adjuncts to standard care.

The holistic, personalized framework of Ayurveda—emphasizing diet, lifestyle, herbal interventions, and mind-body practices—aligns with emerging paradigms in precision medicine and patient-centered care. However, rigorous scientific validation through highquality clinical trials, mechanistic research, and comprehensive safety surveillance remains essential before widespread clinical implementation.

For pediatric endocrinologists, understanding Ayurvedic principles provides cultural competence for the large global population using traditional medicine and offers additional therapeutic tools for challenging cases. For Ayurvedic practitioners, integration with contemporary diagnostic methods and emergency protocols ensures optimal patient safety. Future research should prioritize randomized controlled trials in specific pediatric endocrine conditions, long-term developmental follow-up, pharmacokinetic studies in children, and health economic analyses. The integrative approach holds promise for improving outcomes in pediatric endocrine disorders while honoring traditional healing wisdom and advancing evidence-based practice.

Acknowledgment

The authors acknowledge the academic guidance and institutional support received during the preparation of this review article.

Funding

No external funding was received for the preparation, writing, or publication of this review article.

REFERENCES

1. Palmert MR, Dunkel L. Delayed puberty. N Engl J Med. 2012;366(5):443-453.
2. Melmed S, Auchus RJ, Goldfine AB, Koenig RJ, Rosen CJ, editors. Williams Textbook of Endocrinology. 14th ed. Philadelphia: Elsevier; 2019.
3. Grimberg A, DiVall SA, Polychronakos C, Allen DB, Cohen LE, Quintos JB, et al. Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency. Horm Res Paediatr. 2016;86(6):361-397.
4. Carel JC, Eugster EA, Rogol A, Ghizzoni L, Palmert MR. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics. 2009;123(4):e752e762.
5. Speiser PW, Arlt W, Auchus RJ, Baskin LS, Conway GS, Merke DP, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(11):4043-4088.
6. Patwardhan B, Mutalik G, Tillu G. Integrative Approaches for Health: Biomedical Research, Ayurveda and Yoga. London: Academic Press; 2015.
7. Charak Samhita. Sharma RK, Dash B, translators. Varanasi: Chowkhamba Sanskrit Series Office; 2014.
8. Kaśyapa Saṃhitā. Tiwari PV, editor. Varanasi: Chaukhambha Visvabharati; 2008.
9. Mathur M, et al. Pediatric integrative medicine. Pediatrics. 2017;140(3):e20171961.
10. Arıkan D, Şivrikaya SK, Olgun N. Complementary alternative medicine use in children with type 1 diabetes mellitus in Erzurum, Turkey. J Clin Nurs. 2009;18(12):1776-1784.
11. Li Y, Chen X, Liu Z, Yang J. Chinese herbal medicine for children with idiopathic short stature: a systematic review and meta-analysis. PLoS One. 2022;17(7):e0270511.
12. Charak Samhita. Sharma RK, Dash B, translators. Varanasi: Chowkhamba Sanskrit Series Office; 2014.
13. Frawley D. Ayurveda and the Mind: The Healing of Consciousness. Twin Lakes: Lotus Press; 1997.
14. Sushruta Samhita. Bhishagratna KL, translator. Varanasi: Chowkhamba Sanskrit Series; 2005.
15. Agnivesha. Charaka Samhita. Sutrasthana. Sharma RK, Dash B, translators. Varanasi: Chowkhamba Sanskrit Series Office; 2014.
16. Kaśyapa Saṃhitā. Tiwari PV, editor. Varanasi: Chaukhambha Visvabharati; 2008.
17. Vagbhata. Ashtanga Hridaya. Sutrasthana. Tripathi B, editor. Delhi: Chaukhamba Sanskrit Pratishthan; 2014.

18. Vagbhata. Ashtanga Hridaya. Sutrasthana. Tripathi B, editor. Delhi: Chaukhamba Sanskrit Pratishthan; 2014.
19. Vagbhata. Ashtanga Hridaya. Sutrasthana. Tripathi B, editor. Delhi: Chaukhamba Sanskrit Pratishthan; 2014.
20. Rosenfeld RG. The endocrine system and growth: developmental regulation of endocrine axes. Pediatr Clin North Am. 2019;66(5):975-990.
21. Finkielstain GP, et al. Developmental regulation of the hypothalamic-pituitary-gonadal axis. Endocr Rev. 2018;39(4):439-472.
22. Dayal D, Gupta BM, Gupta A. Thyroid disorders in children and adolescents: systematic mapping of global research over the past three decades. Thyroid Res Pract. 2021;18(1):25-32.
23. Vanderpump MPJ. The epidemiology of thyroid disease. Br Med Bull. 2011;99:39-51.
24. Grimberg A, DiVall SA, Polychronakos C, et al. Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents. Horm Res Paediatr. 2016;86(6):361-397.
25. Libman I, Haynes A, Lyons S, Pradeep P, Rwagasor E, Tung JYL, et al. ISPAD Clinical Practice Consensus Guidelines 2022: definition, epidemiology, and classification of diabetes in children and adolescents. Pediatr Diabetes. 2022;23(8):1160-1174.
26. Bozzola M, Bozzola E, Montalbano C, et al. Delayed puberty versus hypogonadism: a challenge for the pediatrician. Ann Pediatr Endocrinol Metab. 2018;23(2):57-61.
27. Khadilkar V, Shah N, Harish R, et al. Indian Academy of Pediatrics revised guidelines on evaluation, prevention and management of childhood obesity. Indian Pediatr. 2023;60(12):1013-1031.
28. Patwardhan B, Warude D, Pushpangadan P, Bhatt N. Ayurveda and traditional Chinese medicine: a comparative overview. Evid Based Complement Alternat Med. 2005;2(4):465473.
29. Agrawal A, et al. Ayurvedic concepts of Agni and metabolism: a conceptual review. J Ayurveda Integr Med. 2010;1(2):107-112.
30. Chopra A, Doiphode VV. Ayurvedic medicine: core concept, therapeutic principles, and current relevance. Med Clin North Am. 2002;86(1):75-89.
31. Lad V. Textbook of Ayurveda: Fundamental Principles. Albuquerque: Ayurvedic Press; 2002.
32. Frawley D. Ayurveda and the Mind: The Healing of Consciousness. Twin Lakes: Lotus Press; 1997.
33. Charak Samhita. Vimanasthana. Sharma RK, Dash B, translators. Varanasi: Chowkhamba Sanskrit Series Office; 2014.
34. Sarmukaddam S, Chopra A, et al. Efficacy and safety of Ayurvedic medicines: recommending equivalence trial design and proposing safety index. Int J Ayurveda Res. 2010;1(3):175-183.
35. van Trotsenburg P, Stoupa A, Léger J, Rohrer T, Peters C, Fugazzola L, et al. Congenital hypothyroidism: a 2020-consensus guidelines update—an ENDO-European Reference Network initiative endorsed by the European Society for Pediatric Endocrinology and the European Society for Endocrinology. Thyroid. 2021;31(3):387-419.
36. Léger J, Olivieri A, Donaldson M, Torresani T, Krude H, van Vliet G, et al. European Society for Paediatric Endocrinology consensus guidelines on screening, diagnosis, and management of congenital hypothyroidism. Horm Res Paediatr. 2014;81(2):80-103.
37. De Luca F, Santucci S, Corica D, Pitrolo E, Romeo M, Aversa T. Hashimoto thyroiditis in childhood: presentation modes and evolution over time. Ital J Pediatr. 2013;39:73.
38. Panthi S, Gao T. Diagnosis and management of primary hypothyroidism in Traditional Chinese medicine and Traditional Indian Medicine (Ayurveda). Int J Clin Endocrinol Metab. 2015;1(1):009.
39. Dixit AK, Sarkar M, Nair PG, et al. Efficacy of Ayurvedic interventions in hypothyroidism: a comprehensive review. J Res Ayurvedic Sci. 2019;3(4):245-256.
40. Sharma R, et al. Bauhinia variegata and thyroid-related pharmacological activity: experimental evidence. [Verify bibliographic details before submission].
41. Wang H, et al. Ashwagandha and thyroid function: a systematic review of experimental and clinical evidence. [Verify bibliographic details before submission].
42. Panda S, Kar A. Guggulu (Commiphora mukul) as a thyroid stimulator and hypolipidemic agent: experimental evidence. Phytomedicine. 1999;6(5):273-278.
43. Pandit S, Biswas S, Jana U, De RK, Mukhopadhyay SC, De SP. Clinical evaluation of purified Shilajit on testosterone levels in healthy volunteers. Andrologia. 2016;48(5):570577.
44. Kean JD, Downey LA, Stough C. A systematic review of the Ayurvedic medicinal herb Bacopa monnieri in child and adolescent populations. Complement Ther Med. 2016;29:56-62.
45. Sharma VB, Padhar BC, Meena HML, et al. Efficacy of Vyoshadi Guggulu and Shadushana Churna in the management of subclinical hypothyroidism: an open labelled randomized comparative pilot clinical trial. AYU. 2020;41(3):196-203.
46. Gautam S, Padhar BC, Joshi RK. Ayurvedic management of subclinical hypothyroidism. J Karnali Acad Health Sci. 2021;4(2):118-124.
47. Mahdavi. Ayurvedic management of Hashimoto thyroiditis in adolescents. [Case series cited in supplied manuscript; full bibliographic details must be verified].
48. Todkari MS, Dhimdhime RS, Kirte MC, et al. An Ayurvedic management in hypothyroidism: a case study. World J Pharm Res. 2020;9(8):784-792.
49. Dornala. Whole-system Ayurvedic clinical experience in pediatric subclinical hypothyroidism. [Full bibliographic details must be verified].

50. Antonelli A, Ferrari SM, Corrado A, Di Domenicantonio A, Fallahi P. Autoimmune thyroid disorders. Autoimmun Rev. 2015;14(2):174-180.
51. Collett-Solberg PF, Ambler G, Backeljauw PF, Bidlingmaier M, Biller BMK, Boguszewski MCS, et al. Diagnosis, genetics, and therapy of short stature in children: a Growth Hormone Research Society international perspective. Horm Res Paediatr. 2019;92(1):1-14.
52. Cohen P, Rogol AD, Deal CL, Saenger P, Reiter EO, Ross JL, et al. Consensus statement on the diagnosis and treatment of children with idiopathic short stature. J Clin Endocrinol Metab. 2008;93(11):4210-4217.
53. Li Y, Chen X, Liu Z, Yang J. Chinese herbal medicine for children with idiopathic short stature: a systematic review and meta-analysis. PLoS One. 2022;17(7):e0270511.
54. Shim SB, Ahn HL, Lee HH, et al. Effectiveness and safety of combination therapy with herbal medicine and growth hormone compared to growth hormone monotherapy for short stature children: a systematic review and meta-analysis. Evid Based Complement Alternat Med. 2022;2022:5725258.
55. Lee D, Lee SH, Song J, et al. Effects of astragalus extract mixture HT042 on height growth in children with mild short stature: a multicenter randomized controlled trial. Phytother Res. 2018;32(1):49-57.
56. Shim SB, et al. Integrative traditional Korean medicine treatment for idiopathic short stature: clinical effectiveness and bone age effects. Medicine (Baltimore). 2022;101(30):e29960.
57. Ayurvedic case series on Bala Chikitsa for pediatric growth failure. [Bibliographic details not supplied; verify before submission].
58. Carel JC, Eugster EA, Rogol A, Ghizzoni L, Palmert MR. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics. 2009;123(4):e752e762.
59. Latronico AC, et al. Central precocious puberty: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2026;111(8):e1-e35.
60. Vagbhata. Ashtanga Hridaya. Sharirasthana. Tripathi B, editor. Delhi: Chaukhamba Sanskrit Pratishthan; 2014.
61. Biro FM, Wolff MS. Pubertal development and environmental exposures. Curr Opin Endocrinol Diabetes Obes. 2011;18(1):57-64.
62. Goyal R, et al. Asparagus racemosus and reproductive endocrine modulation: experimental review. [Verify bibliographic details before submission].
63. Kean JD, Downey LA, Stough C. A systematic review of Bacopa monnieri in child and adolescent populations. Complement Ther Med. 2016;29:56-62.
64. Nardostachys jatamansi: pharmacological and neuroendocrine effects. [Review; verify bibliographic details before submission].
65. Hemidesmus indicus: phytochemistry and pharmacological activities. [Review; verify bibliographic details before submission].
66. Triphala: phytochemical, pharmacological and clinical evidence review. J Ayurveda Integr Med. [Verify bibliographic details before submission].
67. Kim JH, et al. Herbal medicine (Jogyeongseongjang decoction) for precocious puberty: a systematic review and meta-analysis. Medicine (Baltimore). 2020;99(23):e20587.
68. Gaudino R, De Filippo G, Bozzola E, et al. Current clinical management of constitutional delay of growth and puberty. Ital J Pediatr. 2022;48:112.
69. Cengiz E, Danne T, Ahmad T, Ayyavoo A, Beran D, Ehtisham S, et al. ISPAD Clinical Practice Consensus Guidelines 2022: insulin treatment in children and adolescents with diabetes. Pediatr Diabetes. 2022;23(8):1277-1296.
70. de Bock M, Codner E, Craig ME, et al. ISPAD Clinical Practice Consensus Guidelines 2022: glycemic targets and glucose monitoring for children, adolescents, and young people with diabetes. Pediatr Diabetes. 2022;23(8):1270-1276.
71. Charak Samhita. Chikitsasthana: Prameha. Sharma RK, Dash B, translators. Varanasi: Chowkhamba Sanskrit Series Office; 2014.
72. Sushruta Samhita. Chikitsasthana: Prameha. Bhishagratna KL, translator. Varanasi: Chowkhamba Sanskrit Series; 2005.
73. Madhavakara. Madhava Nidana. Prameha section. Varanasi: Chaukhambha Sanskrit Sansthan; 2012.
74. Dhanavijay A, et al. Tinospora cordifolia: immunomodulatory and antidiabetic pharmacology. J Ayurveda Integr Med. [Verify bibliographic details before submission].
75. Baliga MS, Dsouza JJ. A review of the role of Emblica officinalis in health and disease. Integr Cancer Ther. 2011;10(1):23-36.
76. Chakravarti S, et al. Pterocarpus marsupium and glucose homeostasis: pharmacological review. [Verify bibliographic details before submission].
77. Tiwari P, Mishra BN, Sangwan NS. Phytochemical and pharmacological properties of Gymnema sylvestre: an important medicinal plant. Biomed Res Int. 2014;2014:830285.
78. Subapriya R, Nagini S. Medicinal properties of neem leaves: a review. Curr Med Chem Anticancer Agents. 2005;5(2):149-156.
79. Dannemann K, Hecker W, Haberland H, et al. Use of complementary and alternative medicine in children with type 1 diabetes mellitus—prevalence, patterns of use, and costs. Pediatr Diabetes. 2008;9(3 Pt 1):228-235.
80. McCarty RL, Weber WJ, Loots B, et al. Complementary and alternative medicine use and quality of life in pediatric diabetes. J Altern Complement Med. 2010;16(2):165-173.
81. Haliloğlu B, İşgüven P, Yıldız M, et al. Complementary and alternative medicine in children with type 1 diabetes mellitus. J Clin Res Pediatr Endocrinol. 2011;3(3):139-143.

82. Lemay JF, Amin A, Pacaud D. Complementary and alternative medicine use in children and adolescents with type 1 diabetes. Paediatr Child Health. 2011;16(8):468-472.
83. Khadilkar V, Shah N, Harish R, et al. Indian Academy of Pediatrics revised guidelines on evaluation, prevention and management of childhood obesity. Indian Pediatr. 2023;60(12):1013-1031.
84. Styne DM, Arslanian SA, Connor EL, Farooqi IS, Murad MH, Silverstein JH, et al. Pediatric obesity—assessment, treatment, and prevention: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2017;102(3):709-757.
85. Charak Samhita. Sutrasthana: Santarpanottha Vyadhi. Sharma RK, Dash B, translators. Varanasi: Chowkhamba Sanskrit Series Office; 2014.
86. Lad V. Textbook of Ayurveda: Fundamental Principles. Albuquerque: Ayurvedic Press; 2002.
87. Kaśyapa Saṃhitā. Tiwari PV, editor. Varanasi: Chaukhambha Visvabharati; 2008.
88. Triphala Guggulu: traditional Ayurvedic formulation review. [Verify bibliographic details before submission].
89. Acorus calamus pharmacology and safety review. [Verify bibliographic details before submission].
90. Cyperus rotundus pharmacology and traditional use review. [Verify bibliographic details before submission].
91. Tinospora cordifolia: metabolic and immunomodulatory pharmacology review. [Verify bibliographic details before submission].
92. Ross A, Thomas S. The health benefits of yoga and exercise: a review of comparison studies. J Altern Complement Med. 2010;16(1):3-12.
93. Vachadi Vati in pediatric obesity: case report. J Ayurveda Case Rep. 2020. [Full bibliographic details must be verified].
94. Léger J, Olivieri A, Donaldson M, et al. European Society for Paediatric Endocrinology consensus guidelines on screening, diagnosis, and management of congenital hypothyroidism. Horm Res Paediatr. 2014;81(2):80-103.
95. van Trotsenburg P, Stoupa A, Léger J, et al. Congenital hypothyroidism: a 2020 consensus guidelines update. Thyroid. 2021;31(3):387-419.
96. Kean JD, Downey LA, Stough C. A systematic review of the Ayurvedic medicinal herb Bacopa monnieri in child and adolescent populations. Complement Ther Med. 2016;29:56-62.
97. Newborn screening for congenital hypothyroidism: global and regional evidence review. [Verify bibliographic details before submission].
98. Speiser PW, Arlt W, Auchus RJ, et al. Congenital adrenal hyperplasia due to 21hydroxylase deficiency: Endocrine Society guideline. J Clin Endocrinol Metab. 2018;103(11):40434088.
99. Ashwagandha and adrenal/cortisol effects: systematic review. [Verify bibliographic details before submission].
100. Patwardhan B, Warude D, Pushpangadan P, Bhatt N. Ayurveda and traditional Chinese medicine: a comparative overview. Evid Based Complement Alternat Med. 2005;2(4):465473.
101. Rosenfield RL, Lipton RB, Drum ML. Thelarche, pubarche, and menarche attainment in children: population-based data. Pediatrics. 2009;123(5):e932-e939.
102. Metabolic regulation and Ayurvedic Agni: conceptual review. [Bibliographic details require verification].
103. McEwen BS. Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol Rev. 2007;87(3):873-904.
104. Ingelman-Sundberg M. Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. J Intern Med. 2001;250(3):186-200.
105. Sharma VB, Padhar BC, Meena HML, et al. Efficacy of Vyoshadi Guggulu and Shadushana Churna in the management of subclinical hypothyroidism. AYU. 2020;41(3):196203.
106. Li Y, Chen X, Liu Z, Yang J. Chinese herbal medicine for children with idiopathic short stature: a systematic review and meta-analysis. PLoS One. 2022;17(7):e0270511.
107. Hampl SE, Hassink SG, Skinner AC, et al. Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity. Pediatrics. 2023;151(2):e2022060640.
108. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: a systematic review. Drugs. 2009;69(13):1777-1798.
109. Saper RB, Kales SN, Paquin J, Burns MJ, Eisenberg DM, Davis RB, et al. Heavy metal content of Ayurvedic herbal medicine products. JAMA. 2004;292(23):2868-2873.
110. Cefalu WT, Stephens JM, Ribnicky DM, et al. Herbal medicines and diabetes: safety and efficacy considerations. Diabetes Care. 2008;31(Suppl 2):S125-S129.
111. Panda S, Kar A. Guggulu and thyroid function: experimental evidence. Phytomedicine. 1999;6(5):273-278.
112. Deodati A, Cianfarani S. Impact of growth hormone therapy in children with idiopathic short stature. Nat Rev Endocrinol. 2017;13(1):8-19.
113. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature. 2001;414(6865):799-806.
114. Dhanasekaran M, et al. Tinospora cordifolia and immune/metabolic effects: review. [Verify bibliographic details before submission].
115. Sarmukaddam S, Chopra A, et al. Efficacy and safety of Ayurvedic medicines: recommending equivalence trial design and proposing safety index. Int J Ayurveda Res. 2010;1(3):175-183.
116. World Health Organization. WHO guidelines on good manufacturing practices for herbal medicines. Geneva: World Health Organization; 2007.

117. World Health Organization. WHO traditional medicine strategy: 2014-2023. Geneva: World Health Organization; 2013.
118. Subramanian DK, et al. Pharmacovigilance consideration for Ayurvedic medicines in pediatric practice: developing protocols for documenting clinical safety. J Pharmacol Pharmacother. 2024;15(1):15-24.
119. Weydert JA, Brown M, et al. Integrative medicine in pediatrics. Adv Pediatr. 2018;65:1-13.
120. World Health Organization. WHO global report on traditional and complementary medicine 2019. Geneva: World Health Organization; 2019.